Thrombin activatable fibrinolysis inhibitor in preeclmapsia and gestational hypertension throughout the gestation

Abstract

To clarify the role of TAFI in hypertensive disorders in pregnancy, 22 subjects, including 10 with pre-eclampsia (PE) and 12 with gestational hypertension were examined for the levels of TAFI and thrombin-antithrombin (TAT) complex. Thirty normal pregnant women served as controls. ELISA was employed for the detection. The results showed that the TAFI antigen levels in normal pregnancy group, gestational hypertension group and PE group were (85.35±24.69)%, (99.65±18.27)%, (110.12±23.36)%; (97.06±21.40)%, (114.08±27.76)%, (125.49±24.70)%; (106.6±19.21)%, (129.2±25.07)%, (139.1±30.12)%, in the 1st, 2nd and 3rd trimester respectively. No significant differences were found between the normal pregnancy group and gestational hypertension group but significant difference existed between normal pregnancy group and PE group in each trimester (P<0.05). TAT complexes were significantly higher in patients with PE than that in controls (P<0.05), but no correlation was found between TAT and TAFI. It is concluded that TAFI may contributed to the impairment of fibrinolysis in the patients with PE and may serves as a sensitive indicator for PE, but it may not help in the diagnosis of the gestational hypertension.

Keywords

fibrinolysis / gestational hypertension / pre-eclampsia / thrombin activatable fibrinolysis inhibitor / thrombin-antithrombin complex

References

[1] MyersJ. E., BakerP. N.. Hypertensive diseases and eclampsia. Curr Opin Obstet Gynecol, 2002, 14: 119-125

[2] WalkerJ. J.. PE. Lancet, 2000, 356: 1260-1265

[3] KobayashiT., TokunagaN., SugimuraM., et al.. Predictive values of coagulation/fibrinolysis parameters for the determination of pregnancy complicated by severe PE. Semin Thromb Hemost, 2001, 27: 137-141

[4] PerryK. G., MartinJ. M.. Abnormal hemostasis and coagulopathy in pre-eclampsia and eclampsia. Clin Obstet Gynecol, 1992, 35: 338-345

[5] HalliganA., BonnarJ., SheppardB., et al.. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and PE. Br J Obstet Gynecol, 1994, 101: 488-492

[6] WangW., BoffaM.B., BajzarL., et al.. A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem, 1998, 273: 27176-27181

[7] HoriY., GabazzaE., YanoY., et al.. Insulin resistance is associated with increased circulating level of thrombin activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab, 2002, 87: 660-665

[8] Van TilburgN.H., RosendaalF.R., BertinaR.M.. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood, 2000, 95: 2855-2859

[9] SilveiraA., SchattemanK., GoossensF., et al.. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost, 2000, 84: 364-368

[10] CunninghamF. G., HauthJ. C., KennethJ., et al.. Williams Obstetrics, 200522nd ed.America, McGraw-Hill Companies, Inc.: 567-596

[11] Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol, 2000, 183: S1-S22

[12] BrownM. A.. The physiology of preeclampsia. Clin Exp Pharmacol Physiol, 1995, 22: 781-791

[13] AriasF., Mancilla-JimenezR.. Hepatic fibrinogen deposits in pre-eclampsia. N Engl J Med, 1976, 295: 578-582

[14] McKayD. G.. Hematologic evidence of disseminated intravascular coagulation in eclampsia. Obstet Gynecol Surv, 1972, 27: 399-417

[15] HigginsJ. R., WalsheJ. J., DarlingM. R., et al.. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol, 1998, 179: 520-526

[16] EstellésA., GilabertJ., GranchaS., et al.. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe pre-eclampsia. Thromb Haemost, 1998, 79: 500-508

[17] HendriksD., ScharpéS., van SandeM., et al.. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem, 1989, 27: 277-285

[18] MasudaK., YoshiokaM., HinodeD., et al.. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. Infect Immun, 2002, 70: 1807-1815

[19] ChetailleP., AlessiM. C., KouassiD., et al.. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost, 2000, 83: 902-905

[20] ChablozP., ReberG., BoehlenF., et al.. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol, 2001, 115: 150-152

[21] AntovicJ. P., RafikH. R., AntovicA., et al.. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with pe and/or intrauterine fetal growth retardation?. Thromb Haemost, 2002, 88: 644-647

[22] AlacacioğluI., OzcanM. A., AlacacioğluA., et al.. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res, 2004, 114: 155-159

[23] HenryM., AubertH., MorangeP. E., et al.. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood, 2001, 97: 2053-2058

[24] FrancoR. F., FagundesM. G., MeijersJ. C., et al.. Identification of polymorphisms in the 5′-untranslated region of the tafi gene: relationship with plasma tafi levels and risk of venous thrombosis. Haematologica, 2001, 86: 510-517

[25] De MaatM. P., JansenM. W., HilleE. T., et al.. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost, 2004, 9: 1588-1593

[26] ChaiworapongsaT., YoshimatsuJ., EspinozaJ., et al.. Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med, 2002, 11: 362-367

[27] KobayashiT., TokunagaN., SugimuraM., et al.. Coagulation/fibrinolysis disorder in patients with severe PE. Semin Thromb Hemost, 1999, 25: 451-454

[28] CadroyY., GrandjeanH., PichonJ., et al.. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol, 1993, 100: 416-420